Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam European Patent Upheld by Opposition Board

Premium

Alnylam Pharmaceuticals this week announced that the European Patent Office has upheld one of the company's RNAi-related patents in oral proceedings held before the office's opposition board.

The patent, No. EP 1352061, was the first to be granted in Europe from the company's so-called Kreutzer-Limmer II patent family.

The company said that the patent, which includes claims covering methods of silencing about 130 genes using siRNAs of up to 49 nucleotides in length, had been challenged by Merck subsidiary Sirna Therapeutics.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.